Home » FibroGen Initiates Phase 2/3 Trial in Italy of Pamrevlumab for Severe COVID-19
FibroGen Initiates Phase 2/3 Trial in Italy of Pamrevlumab for Severe COVID-19
FibroGen has launched a phase 2/3 trial in Italy to evaluate pulmonary fibrosis treatment pamrevlumab in severe COVID-19 patients.
The trial will include 68 hospitalized patients who will receive either pamrevlumab or standard of care.
The company also plans to initiate two phase 2 trials in the U.S. to assess pamrevlumab vs. standard of care in patients with severe COVID-19.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May